RVPH Stock Earnings: Reviva Pharmaceuticals Beats EPS for Q1 2024

Written By Michael Gary Scott







Analysis: Reviva Pharmaceuticals Surpasses Analyst Estimates in Q1 2024

Strong Start for Reviva Pharmaceuticals

RVPH stock - RVPH Stock Earnings: Reviva Pharmaceuticals Beats EPS for Q1 2024

Source: iQoncept / Shutterstock

Reviva Pharmaceuticals (NASDAQ:RVPH) recently announced its results for Q1 2024.

  • Reviva Pharmaceuticals exceeded expectations by reporting earnings per share of -25 cents, surpassing the anticipated -42 cents.
  • The company did not disclose any revenue figures for the quarter.

It seems like Reviva Pharmaceuticals is off to a promising start in 2024, outshining the predictions set by analysts.


Stay tuned for further updates on Reviva Pharmaceuticals as the year progresses.


See also  Cisco Set For Technical Breakout As Golden Cross Signals Strength: Analyst Predicts Stock Will 'Quietly' Climb Higher